Herpes simplex virus thymidine kinase (HSV-tk) gene transfer and ganciclovir (GCV) administration have been suggested for the treatment of malignant gliomas. To understand tissue responses and possible ways to improve the treatment effect, we studied tumor growth, tissue reactions, and survival time after HSV-tk/GCV treatment in a syngeneic BT4C rat glioma model by mixing various ratios of stably transfected HSV-tk-expressing BT4C-tk glioma cells with wild-type BT4C glioma cells (percentage of BT4C-tk cells: 0%, 1%, 10%, 30%, 50%, and 100%), followed by injection into BDIX rat brains (n ϭ 79). With the exception of some animals with end-stage tumors, very little astroglia or microglia reactivity was detected in the wild-type tumors as analyzed by immunocytochemistry using glial fibrillary acid protein (GFAP)-, vimentin-, human histocompatibility leukocyte antigen-DR-, OX-42-, and CD68-specific monoclonal antibodies. After 14 days of GCV treatment, tumors induced with Ն10% BT4C-tk cells showed a significant reduction in tumor size (P Ͻ .05) and prolonged survival time (P Ͻ .01). Astrogliosis, as indicated by a strong GFAP and vimentin immunoreactivity, was seen in the tumor scar area. GFAP and vimentin reactivity was already present after the GCV treatment in tumors induced with 1% BT4C-tk cells. Much less human histocompatibility leukocyte antigen-DR-positive microglia was seen in the treated animals, indicating low microglia reactivity and immunoactivation against the tumor. However, GCV-treated tumors were positive for apoptosis, indicating that apoptosis is an important mechanism for cell death in the BT4C-tk glioma model. Our results suggest that Ն10% transfection efficiency is required for a successful reduction in BT4C glioma tumor size with HSV-tk/GCV treatment in vivo. Tissue reactions after 14 days of GCV treatment are characterized by astrogliosis and apoptosis, whereas microglia response and immunoactivation of the brain cells appear to play a minor role. Stimulation of the microglia response by gene transfer or other means might improve the efficacy of the HSV-tk/GCV treatment in vivo. Cancer Gene Therapy (2000) 7, 413-421
D espite aggressive treatment, the prognosis of patients with malignant glioma is extremely poor. The median survival time is 14 months, and a reasonable quality of life is limited to even shorter periods of time. Glioblastoma is the most aggressive glioma, with an average survival time of 10 months. 1 In recurrent glioblastoma, mortality is nearly 100% within a few months. 2 During the last 15 years, the prognosis of glioblastoma has not changed despite improvements in surgery and radiation therapy. 3 Thus, new therapeutic approaches are urgently needed.
Gene therapy may offer a new strategy for the treatment of malignant gliomas. The most widely used gene therapy approach for the treatment of glioma involves the transfer of herpes simplex virus thymidine kinase (HSV-tk), followed by ganciclovir (GCV) administration. 4 -7 HSV-tk can be delivered into the brain with many vectors, such as plasmid-liposomes, retroviruses, retroviral packaging cells, and adenoviruses. 8, 9 Brain tumors are well suited for retrovirus-mediated gene therapy, because neurons show no proliferative activity and retroviral vectors can only transfer genes to proliferating cells. 5, 10 Adenoviruses have also successfully been used for gene transfer to malignant gliomas. 11, 12 Transfer of the HSV-tk gene renders cells sensitive to GCV treatment. HSV-tk catalyzes the phosphorylation of GCV to a cytotoxic nucleotide analog that blocks DNA replication and kills transfected cells. 4, 5 The therapeutic effect of HSV-tk is further enhanced by the so-called bystander effect, in which the toxic effect spreads from the transfected cells to the neighboring untransfected cells. 11, 13 The mechanism of the bystander effect is not fully understood, but may involve the release of cytotoxic nucleotide analogs to neighboring cells through gap junctions or activation of inflammatory and immunological responses mediated by cytokines and surrounding brain cells.
14 However, very little data are available with regard to tissue reactions (astroglia, microglia, inflammatory cells) in the HSV-tk/GCV-treated tumors. Knowledge about the type and extent of cellular reactivity should help us to improve the efficacy of the HSV-tk/GCV treatment effect.
A typical feature of human malignant glioma is that it is virtually invisible to the human immune system. Several rat glioma models have been used to model malignant glioma tumors in experimental studies; however, many widely used syngeneic models, such as 9L gliosarcoma, can be immunogenic. 15 Another widely used model, C6 glioma, is not syngeneic and induces immune responses that can affect therapeutic efficacy and survival. 15 In the present study, we describe the BT4C rat glioma model for the evaluation of the effectiveness of HSV-tk/ GCV treatment and tissue reactions in the BDIX rat brain. The model resembles human glioma in many aspects, including its ability to grow without inducing any significant tissue reactions against the tumor. Our results show that Ն10% HSV-tk-positive glioma cells are required for a successful treatment effect. Tissue reactions after the HSV-tk/GCV treatment were characterized by astrogliosis and apoptosis, with only moderate involvement of microglia and immunoactivation of brain cells.
MATERIALS AND METHODS

Cell lines and viral vectors
A BT4C rat glioma cell line was derived from fetal BDIX rat brain cells, which were transferred to monolayer cell culture shortly after in vivo exposure to N-ethylnitrosourea. BT4C cells have been characterized elsewhere. 16 The cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf sera, 1% penicillin/streptomycin, and nonessential amino acids (Life Technologies, Paisley, UK). A total of 1.2 kb of HSV-tk cDNA 17 (GenBank accession no. V00470) was subcloned into EcoRI-XhoI sites of the pLXSN retroviral plasmid 18 (kindly provided by Dr. A. Dusty Miller, Fred Hutchinson Cancer Research Center, Seattle, Wash) (Fig 1) . The expression of the HSV-tk cDNA is driven by a 5Ј Moloney murine sarcoma virus long terminal repeat (LTR). A PA317 packaging cell line 18 was used for the packaging of replicationdeficient amphotropic viruses. A stable producer clone (clone Figure 2 . Effectiveness of HSV-tk gene transfer and GCV treatment in stably transfected rat BT4C-tk glioma cells. A: The optimal concentration of GCV was determined in BT4C-tk cells by plating 1 ϫ 10 4 cells on 35-mm plates and incubating the cells with indicated concentrations of GCV for 4 days. The 50% lethal dose for GCV in transfected cells is ϳ0.1 g/mL. B: The bystander effect was studied in vitro by mixing different percentages of BT4C-tk cells and wt BT4C cells, followed by GCV incubation (2 g/mL) for 6 days. Each experiment was performed in triplicate and repeated twice (mean Ϯ SD). 3.0 D5) was obtained after geneticin selection. Viral titers of 1 ϫ 10 5 to 1 ϫ 10 6 colony-forming units/mL were produced by the selected clone 3.0 D5. A similar virus lacking HSV-tk cDNA but containing the neomycin resistance gene was produced in PA317 cells and used as a control "empty" virus (titer of 0.5-1 ϫ 10 6 colony-forming units/mL). Viral titers were determined in 209F fibroblasts as described previously. 19 Before use, the packaging cell lines and virus lots were shown to be free of any helper virus activity, endotoxin, mycoplasma, or other types of microbiological contaminants. 20 
In vitro studies
Rat BT4C glioma cells were transduced with replicationdeficient HSV-tk retroviruses or control empty retroviruses. Stably transduced BT4C-tk and BT4C control cell lines were isolated using standard techniques. 18 Sensitivity to GCV treatment of the BT4C-tk cell line and wild-type BT4C control cell line was determined in vitro using five different drug concentrations: 0 g/mL, 0.01 g/mL, 0.1 g/mL, 1 g/mL, 10 g/mL, and 100 g/mL (Cymevene, Syntex Nordica Ab, Södertälje, Sweden). Stably transduced BT4C cell lines and wild-type (wt) BT4C cells were grown in DMEM as described above. On day 1, 1 ϫ 10 4 cells were seeded on 35-mm wells (Nunc, Roskilde, Denmark). Growth medium containing the indicated concentrations of GCV was added 24 hours later and replaced on day 3. Cells were trypsinized on day 5, and the number of cells in each well was counted (Bürker, Marienfeld, Germany). The bystander effect was evaluated in vitro by mixing increasing percentages (1%, 5%, 10%, 30%, 50%, and 100%) of BT4C-tk-positive glioma cells with wt BT4C glioma cells. On day 1, cell mixtures were seeded at a total of 4 ϫ 10 5 cells per 35-mm well. Growth medium containing 2 g/mL GCV was added 24 hours later and replaced every 2 days. After 6 days of GCV treatment, cells were suspended and counted as described above. Results are presented as percentages of the number of treated cells from the number of wt cells cultured without GCV under identical conditions.
In vivo studies
Intracranial implantations of BT4C glioma cells were performed in inbred male BDIX rats (290 -410 g). Because the BT4C glioma cell line was originally derived from BDIX rats, the model does not induce any adverse host-tumor tissue or immunological reactions. 21 The rats were anesthetized intra- peritoneally (i.p.) with 0.4 mL/100 g of a solution containing 4.25% chloral hydrate and 0.97% pentobarbital and placed in a stereotactic apparatus (Kopf, Berlin, Germany). A burr hole was done 1 mm posterior to the bregma and 2 mm to the right of the midline. The dura was incised with a needle. For cell injections, BT4C-tk and wt glioma cells were trypsinized, counted, and collected by centrifugation. The cells were resuspended in DMEM to a final concentration of 10,000 cells in 5 L. Cells were injected (10 4 cells in 5 L of DMEM) with a 10-L Hamilton syringe (Hamilton, Bonaduz Ab, Switzerland) that was placed in a microinjection unit of the stereotactic frame. Injection was made at the depth of 3 mm within the right corpus callosum. 22 To avoid backflow of the tumor cells, the injection was done during a 5-minute period; the needle was left in place for another 5 minutes before removal. Skin incision was closed with stitches (4-0 Dexon, Davis and Geck, Hampshire, UK).
The rats were divided into six groups, which were used for morphometric and immunocytochemical analysis as follows: Group I (n ϭ 10) received wt BT4C glioma cells; group II (n ϭ 3) received BT4C control cells transfected with empty virus; group III (n ϭ 4) received 1% BT4C-tk cells and 99% wt BT4C cells; group IV (n ϭ 5) received 10% BT4C-tk cells and 90% wt BT4C cells; group V (n ϭ 5) received 30% BT4C-tk cells and 70% wt BT4C cells; and group VI (n ϭ 13) received only BT4C-tk cells. For the survival study, the following number of animals was used: Group I (n ϭ 6), group II (n ϭ 3), group III (n ϭ 6), group IV (n ϭ 7), group V (n ϭ 6), and group VI (n ϭ 11). In the survival study, group V consisted of animals injected with 50% BT4C-tk cells and 50% wt BT4C cells. All animals in groups II-VI received i.p. GCV treatment (25 mg/kg) twice a day for 2 weeks. The treatment was started 10 days after the glioma cell injection. Group I (control group) showed the natural course of the disease. Three additional control animals with wt tumors were sacrificed 10 days after the tumor cell injections to study early tissue reactions against the tumor. Animals for morphological analyses were sacrificed after the GCV treatment period. Animals in the survival study were followed for 6 months.
Immunocytochemistry and image analysis
The rats were perfused with 100 mL of phosphate-buffered saline and 4% paraformaldehyde for 10 minutes. The brains were dissected and divided at the injection site into two coronal pieces. The tissue samples were further fixed in 4% paraformaldehyde for 18 hours and rinsed overnight in 15% sucrose. 23 Paraffin sections were either stained with hematoxylin-eosin (BDH, Poole, Dorset, UK) or immunostained with monoclonal antibodies (mAbs) against glial fibrillary acid protein (GFAP) (dilution 1/100, Boehringer-Mannheim, Mannheim, Germany), CD68 (dilution 1/100, Dako, Glostrup, Denmark), EBM-11 (dilution 1/25, Dako), OX-42 (dilution 1/500, Serotec, Kidlington, Oxon, UK), or human histocompatibility leukocyte antigen (HLA)-DR CR43 (dilution 1/100, Dako). With some antibodies (Abs), microwave oven incubation in citric acid buffer was used to improve the immunostainings. An avidin-biotin-horseradish peroxidase system (Vector Elite, Vector Laboratories, Burlingame, Calif) was used for signal detection. Apoptosis was detected using an ApopTag Plus kit (Oncor, Gaithersburg, Md). Rat spleens and lymph nodes and normal human tonsils and brain tissue obtained from biopsy material were used as positive controls for immunostainings. The negative controls included incubations with glass-and species-matched unrelated immunoglobulins (Igs) and incubations in which primary Abs were omitted. 23, 24 Tumor sizes were determined with a computerized image analysis system (MCID Software, Imaging Research, St. Catharines, Ontario, Canada) from histological sections by measuring the tumor area (pixels) at the level of the injection site. The tumor area was standardized against the total brain area measured from the same section.
Magnetic resonance imaging (MRI)
MRI was used for the visualization of the tumors. For imaging, the rats were anesthetized as described above. The rats received contrast enhancer i.p. (Magnevist, License Schering AG Pharma, Berlin, Germany; 0.3 mL in 0.7 mL of physiological salt solution), and MRI was performed with a superconducting whole body system (Siemens, Vision, Erfangen, Germany) operating at 1.5 T using a small field of view surface coil. T1-and T2-weighted spin-echo sequences were used. The imaging parameters for the T1-weighted images were as follows: 500/20 (repetition time, TR/echo time, TE; ms) with four acquisitions and imaging time of 8:36 minutes. Proton and T2-weighted images were acquired with a TR/TE of 2000/20 and 76 ms (imaging time of 8:36 minutes) with one acquisition. Slice thickness was 2 mm with both sequences, and a 60-to 100-mm field of view was used. A 256 ϫ 256 imaging matrix yielded in-plane resolution of 0.23-0.39 mm.
Statistical analysis
The Kruskal-Wallis test for pairwise comparisons between tumor sizes in the treatment groups was made using BMDP 1.0 software for Windows (Imaging Research, St. Catharine's, Ontario, Canada). Statistical analyses for survival data were performed using the SPSS for Windows (SPSS Inc., Chicago, IL) log-rank test for Kaplan-Meier plots.
RESULTS
HSV-tk and GCV treatment in BT4C glioma cells in vitro
The efficacy of the HSV-tk gene transfer and GCV treatment was verified in BT4C cell cultures. A total of 1 g/mL GCV was able to kill 91% of the BT4C-tk glioma cells in 4 days, whereas no effect was detected in wt BT4C cells at a low concentration of GCV (Fig 2A) . In separate experiments, no effect of GCV treatment on BT4C control cells transfected with empty virus was detected (data not shown). The bystander effect was evaluated in vitro by mixing different percentages of BT4C-tk-positive glioma cells with wt BT4C glioma cells. Cultures were then subjected to GCV treatment for 6 days. Our results showed that 10% and 30% of BT4C-tk glioma cells were able to kill 78% and 86% of all cells (Fig 2B) .
Characterization of the BT4C glioma model in vivo
Histology, immunocytochemistry, and MRI were used for the characterization of the BT4C rat glioma model in vivo (Fig 3) . All rats in the control group (group I) injected with 1 ϫ 10 4 wt BT4C glioma cells developed macroscopic tumors. It has been determined previously that the mean survival time of the animals with wt tumors is 39 days (range 18 -60 days, A.-M.S., K.T., and S.Y.-H. unpublished observations). The site, size, and shape of the tumors in the contrast-enhanced MRI images correlated well with the histological findings (Fig  3) . Immunocytochemistry showed that at the early stage, animals with wt tumors had no immunostaining in the tumor area for GFAP or vimentin (see below), indicating a low level of astroglia reactivity against the tumor (Table 1 ; Fig 3C) . At the late stage, some positive astroglia reactivity was observed (Table 1 ; Fig 3F) . Very little microglia reactivity, as evaluated by CD68, HLA-DR, and OX-42 immunocytochemistry, was present in the tumor area (Table 1 , see below). Thus, the rat BT4C glioma model resembles human glioblastoma in that it does not induce strong tissue reactions against the tumor. However, GFAP (Fig 3I) and vimentin (data not shown) immunostainings were clearly detectable around the tumor after gene therapy only 3 days after the beginning of the GCV treatment.
Characterization of the treatment effect in the BT4C glioma model in vivo Macroscopic tumors were present in all group III (1% BT4C-tk-positive cells) rats (Table 1; Fig 4, D-F) . In group IV (10% BT4C-tk-positive cells), two of five rats had small residual tumors at the brain cortex that were probably caused by spilling of the tumor cells through the injection canal. Intracerebral tumors in the deeper areas of brain were not detected in group IV animals, but a low cell density scar was present at the site of injection (Table 1; Fig 4, G-I) . In group V (30% BT4C-tk-positive cells), one of five rats had a small tumor at the brain cortex. The same animal also had some remaining tumor cells within the scar area. No other tumors were detected in group V animals. The group VI (100% BT4C-tk-positive cells) animals had no tumors (Table 1; Fig 4, J-L) . A scar formation was observed at the injection site in all group VI animals ( Fig 4L) .
GFAP and vimentin immunocytochemistry (Fig 3C;  Fig 4 , B and C) in group I showed a limited astroglia reaction in the wt tumors. With only 1% BT4C-tkpositive cells (group III), the frequency of positive GFAP and vimentin immunostainings had clearly increased around the tumor (Fig 4, E and F) . This finding indicates that even if the tumor cannot be eradicated, the treated tumor stimulates astroglia reactions. Only a few HLA-DR-positive cells (Fig 5, A and B) or OX-42-positive cells (data not shown) were detected in any of the tissue sections, indicating that microglia activation and/or an influx of blood monocyte-macrophages does not play a major role in defense and tissue reactions at the time of sacrifice (Table 1) . However, apoptotic cells were more frequently detected in the treated tumors than in the wt glioma (Fig 5, C and D) . The findings suggest that apoptosis is an important mechanism for cell death after HSV-tk/GCV treatment.
The treatment effect was already visible in group IV (10% BT4C-tk-positive cells), in which only two animals had residual tumors at the brain cortex. These cortical tumors were counted as recurrent tumors and were included in the measurements ( Table 1 ). The tumor sizes were small compared with the tumors in group I-III animals (Table 1; Fig 4, G-I) . The treatment effect was also evident in group V (30% BT4C-tk-positive cells). Thus, it appears that Ն10% BT4C-tk-positive cells can lead to a successful reduction in tumor size. However, in one treated animal in Group V, remaining glioma cells were still detected at the brain cortex; only 100% BT4C-tk cells could be fully eradicated with the GCV treatment ( Table 1) .
All animals that were left for a long-term follow-up in 
The size (pixels) of the tumors was measured with an image analysis system as described in Materials and Methods. To analyze tissue reactions during the natural course of the disease, group I animals were allowed to develop end-stage tumors and were not included in the statistical analysis. Tumor size in group II versus group III: not significant; group II versus group IV: P Ͻ .05; group II versus group V: ‫ء‬P Ͻ .05; group II versus group VI:‫ءء‬P Ͻ .01 (Kruskal-Wallis test). Astroglia and microglia responses were evaluated after the immunostaining of 10 randomly selected sections from each animal for GFAP and vimentin (astroglia) and for CD68 and OX-42 (microglia). Ϫ, absent or weakly positive in less than half of the sections; ϩ, weakly positive in more than half of the sections; ϩϩ, moderately positive in all sections; ϩϩϩ, strongly positive in all sections.
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group VI (HSV-tk 100%) survived for Ͼ6 months. Survival was also significantly (P Ͻ .01) prolonged with animals with 10% and 50% HSV-tk-positive cells (Fig  6) . No difference was found in survival between wt BT4C glioma cells and empty virus-transfected control BT4C cells (Fig 6) .
DISCUSSION
Current treatment strategies have failed to improve the prognosis of patients with glioblastoma, which is one of the most lethal human cancers. Gene therapy may offer a new strategy for the treatment of malignant glioma. In this study we used the syngeneic BT4C glioma model in BDIX rats. The model was chosen because the wt BT4C cells mimic human malignant glioma in that they induce very few tissue reactions when injected into the brain of a BDIX rat. Also, MRI can be used to follow-up the growth of the tumors without sacrificing the animals, and BT4C glioma cells can easily be transfected with Moloney murine-derived retroviruses or adenoviruses. 25 MRI was also used to ensure the existence of tumors before GCV treatment. Thus, the model is very useful for studies related to human glioblastoma.
Our results show that, both in vitro and in vivo, Ն10% BT4C-tk-expressing cells among wt BT4C glioma cells are required for a beneficial GCV treatment effect. The results are in line with previously published findings from 9L and C6 glioma models 5,26 -30 and indicate that the bystander effect also occurs in the BT4C cells. Our results confirm the important role of the bystander effect in the treatment of experimental gliomas. 31 9L and C6 glioma cells that express HSV-tk have been eliminated in nude mice or rat brains after the GCV treatment, and complete remissions have been reported in 50 -78% of the treated animals. 5,26 -30 However, there are also reports indicating that HSV-tk gene transfer followed by GCV treatment does not lead to a complete eradication of glioma in the rat brain. 32, 33 The reason for the discrepancy in HSV-tk/GCV results is currently unclear, but may involve different cell lines or conditions used for the gene transfer and GCV treatment. Also, differences in tissue reactions in various experimental glioma models probably affect the final outcome. 15 Animals in group VI (100% BT4C-tk-positive cells) were followed for up to 6 months without tumor recurrence. Significantly prolonged survival in animals with 10 -50% HSV-tk-positive cells was also observed. The results correlate well with histological findings from animals sacrificed after the GCV treatment. It is noteworthy that in group V (50% BT4C-tk-positive cells), one animal still had some cancer cells in the treated area; in addition, residual tumors at the brain cortex were present in two group IV (10% BT4C-tk-positive cells) animals. It is likely that tumor recurrence will occur in some HSV-tk/GCV-treated animals even if the gene transfer efficiency is high. Thus, despite the effective short-term antitumoral effects, HSV-tk/GCV treatment may not solve the problem of tumor recurrence. It is possible that the long-term survival could be improved by stimulation of an immune response toward inoculated glioma cells; in other glioma models that have shown a better treatment effect, such as 9L, rich cellular infiltrates containing microglia, macrophages, and T cells have been reported after HSV-tk/GCV treatment. 34 Our results show that tissue reactions against stably transfected BT4C-tk glioma cells are almost exclusively derived from astroglia. Apoptosis seems to be an important mechanism for cell death, as also demonstrated by others. [35] [36] [37] [38] However, only limited CD68, HLA-DR, or OX-42 immunoreactivity (microglia or macrophages) was detected in the treated area, which is a normal feature for BT4C tumors. A better understanding of tissue reactions, of the time course of the immunological responses, and of patterns of gene expression in cells surrounding the tumor may prove essential for the improvement of the treatment effect.
With current gene transfer techniques, Ն10% transfection efficiency can be obtained in the vicinity of the gene transfer site in human glioma tumors in vivo. 20 However, the overall transfection efficiency in human glioma tumors is still very low because the number of cells in the vicinity of the transfection site is low compared with the total tumor mass. 20 According to our results and evidence published elsewhere, 7, 32, 33 it is likely that in human clinical trials based on HSV-tk/ GCV treatment, residual glioma cells will remain in the brain. Because astrogliosis and apoptosis are the major responses in the BDIX rat brain after the cytotoxic effect of GCV treatment, it is unlikely that effective immune responses will develop toward malignant cells. Accordingly, stimulation of microglia-related inflammatory and immunological reactions by combined gene transfer of HSV-tk and cytokines such as interleukin-2 (IL-2), IL-3, IL-12, or macrophage colony-stimulating factor might improve the effectiveness of the HSV-tk/GCV treatment, especially when only low transfection efficiencies can be obtained. Group I versus group II: not significant; group I versus group III: not significant; group I versus group IV, P Ͻ .01; group I versus group V, P Ͻ .01; group I versus group VI, P Ͻ .01 (log rank test for Kaplan-Meier survival plots). Number of animals studied in each group: I ϭ 6, II ϭ 3, III ϭ 6, IV ϭ 7, V ϭ 6, and VI ϭ 11.
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